InMed Pharmaceuticals Inc. (MTRI) company profile

InMed Pharmaceuticals Inc. is a pharmaceutical drug development company engaged in the research and preclinical development of proprietary small molecule drug candidates. The company focuses on developing preferential signaling ligands targeting cannabinoid CB1 and CB2 receptors and other disease-related pathways. Its research pipeline includes INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755 cannabinol cream for epidermolysis bullosa and itch-related conditions. InMed previously operated a commercial operations segment through BayMedica, which constituted its sole revenue-generating unit before being completely wound down. The company aims to advance its pipeline toward clinical trials and pursue licensing or commercial partnerships.

Originally established in British Columbia, Canada, the company operates with a lean organization of six full-time employees and external consultants. InMed maintains its principal mailing address in Vancouver, British Columbia, Canada, and no longer occupies physical executive office space. Its intended regulatory activities and target clinical development span major global jurisdictions, including planned applications in the United States.

Summary of the business section of InMed Pharmaceuticals's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“As of September 1, 2026, inclusive of our management team, we had 6 full-time employees, and we also utilize the services of several consultants.”